Human Vaccines & Immunotherapeutics (Nov 2021)

Economic evaluation of varicella vaccination strategies in Jiangsu province, China: a decision-tree Markov model

  • Qiang Wang,
  • Shixin Xiu,
  • Liuqing Yang,
  • Jinxin Huang,
  • Tingting Cui,
  • Naiyang Shi,
  • Xuwen Wang,
  • Yuan Shen,
  • Enpin Chen,
  • Bing Lu,
  • Hui Jin,
  • Leesa Lin

DOI
https://doi.org/10.1080/21645515.2021.1958608
Journal volume & issue
Vol. 17, no. 11
pp. 4194 – 4202

Abstract

Read online

This study evaluated different varicella vaccination strategies in Jiangsu province, China. A decision-tree Markov model was used to evaluate the cost effectiveness of various varicella vaccination strategies for children, including direct and selective vaccination (serotesting pre-vaccination). A cohort of one-year-old children was followed through 60 one-year Markov cycles. The parameter estimation was based on field work, the literature, and statistical yearbooks. We calculated the incremental cost-utility ratio (ICUR) using the saved quality-adjusted life year (QALY). One-way and probability sensitivity analyses were performed to assess uncertainty. Among 100,000 cohort members, one-dose and two-dose direct vaccination averted 8061 and 10,701 varicella cases, respectively, compared with no vaccination. Furthermore, compared with no vaccination, one-dose and two-dose direct vaccination saved one QALY at the ICUR of USD 21,401.33 and USD 35,420.81, respectively, at less than three times the per capita gross domestic product (USD 47,626.86) of Jiangsu. The ICURs of the one-dose and two-dose selective strategies versus no vaccination were USD 42,623.62 and USD 51,406.35 per QALY gained, respectively. The cost effectiveness results were most sensitive to the QALY loss of outpatients and vaccine prices. Thus, in Jiangsu, one-dose and two-dose direct varicella vaccination in children could be cost effective at the willingness to pay threshold of three times provincial GDP per capita from a societal perspective. The findings were sensitive to the vaccine price and health utility of varicella cases.

Keywords